Search
Search
T cell processing often involves variable starting materials and hands-on steps that can lead to manufacturing inconsistencies. Dynabeads cell separation technology offers a structured approach to establishing defined isolation and activation, helping teams develop more consistent upstream processes. By supporting controlled early interactions in closed, GMP-ready formats, Gibco CTS Dynabeads magnetic beads help programs build a reliable foundation for later manufacturing stages.
CTS Dynabeads magnetic beads support defined T cell isolation, activation, and depletion by bringing highly specific surface ligands into controlled contact with target cells. Built on a uniform paramagnetic structure, the beads help create steady interaction conditions during early processing steps, supporting reproducible isolation and activation within closed bioprocessing workflows.
| Targeted binding | Active release | Magnetic removal | Buffer exchange and cleanup |
| Single-domain VHH antibodies on the bead surface bind defined CD markers to support selective T cell isolation or activation (1). | After cell separation, the biotin-based Gibco CTS Detachable Dynabeads Release Buffer is added (2) to actively detach beads through a competitive displacement mechanism that releases the biotin derivative on the bead surface (3). | Once detached, CTS Detachable Dynabeads magnetic beads can be magnetically collected and separated from the cell population (4). | Subsequent washes remove the CTS Detachable Dynabeads Release Buffer and remaining components (5), helping generate a highly pure, viable T cell population, including subsets that maintain early memory or stem-like phenotypes. |
Establish reliable early T cell isolation and activation with Dynabeads cell separation technology that supports defined interactions from the start of the process. In addition to isolation and activation, the CTS Dynabeads portfolio includes CD3⁺ cell depletion solutions, expanding support for allogeneic T cell manufacturing workflows that require precise cell population control. The consistent bead composition and well-documented manufacturing framework help reduce cell therapy processing variability between runs and maintain steady operation as workflows evolve. This dependable performance offers programs a stable foundation for moving from development into larger-scale manufacturing.
Some T cell workflows require early activation and controlled bead release for modification and expansion. Gibco CTS Detachable Dynabeads magnetic beads address this need by combining selective binding with the option to release beads at a defined timepoint using the CTS Detachable Dynabeads Release Buffer. This approach helps teams manage activation windows with greater control and move into downstream steps without carrying beads forward. Designed for use in closed, GMP-ready systems, including the CTS DynaCellect Magnetic Separation System, the detachable format supports flexibility across autologous and allogeneic processes.
Established T cell processes often rely on solutions that support predictable activation and steady expansion throughout development. CTS Dynabeads magnetic beads offer a consistent option for programs that use a fixed-activation approach with passive bead release.
Integrate Dynabeads cell separation technology with cell therapy products to support consistent handling from isolation through final processing.
CTS Dynabeads magnetic beads are used to isolate and activate T cells through defined CD3/CD28 engagement in closed, GMP-ready workflows. They support early steps in both autologous and allogeneic manufacturing and are part of a portfolio of cell therapy products designed to be used together.
CTS Dynabeads magnetic beads are designed to activate T cells by bringing CD3 and CD28 markers into close proximity, enabling coordinated signaling required for defined activation. When the beads bind to the cell surface, this clustering event initiates early signaling pathways that guide proliferation and phenotype development. Because the beads can be magnetically separated without centrifugation, activation steps can be performed in closed systems, enabling consistent handling across runs.
Dynabeads cell separation technology has been incorporated into the manufacturing process for FDA-approved CAR-T therapies, particularly in processes involving T cell isolation, activation, and expansion within commercial manufacturing workflows. CTS Dynabeads magnetic beads are intended for research use or further manufacturing, consistent with regulatory requirements for cell-based therapeutics.
CTS Detachable Dynabeads CD3/CD28 beads include an active, biotin-based release mechanism that allows users to remove beads from T cells at their selected time using the CTS Dynabeads Release Buffer. This active release offers greater control over isolation and activation steps and can shorten bead removal times. Standard CTS Dynabeads CD3/CD28 beads use passive bead release, after which the beads are magnetically separated, and therefore do not offer timed, user-directed detachment.
CTS Detachable Dynabeads magnetic beads can be used in both autologous and allogeneic T cell workflows. Their active release mechanism supports process designs that require controlled bead removal, making them adaptable across different manufacturing approaches.
CTS Detachable Dynabeads magnetic beads are designed to work directly with the CTS DynaCellect Magnetic Separation System for closed, automated processing. They can also be used with Gibco CTS DynaMag Magnets for small-scale or early development workflows, allowing flexibility across process stages while maintaining consistent handling conditions.
*For Research Use Only. Not for use in diagnostic procedures. Product is a prototype and performance characteristics of this product have not been established.
For Research Use or Manufacturing of Cell, Gene, or Tissue-Based Products. CAUTION: Not intended for direct administration into humans or animals.